10 Gilead business development leaders
These Gilead business development leaders hold vice president, executive director, senior director and director titles in search and evaluation, alliance management and corporate development. A reader can learn how business development leaders work at Gilead from people who have held the role.
Professionals to explore
Alison Blaschke Benner
LinkedInExperience: Director, Alliance Management · Gilead Sciences
Alison Blaschke Benner has been Director, Alliance Management at Gilead Sciences since November 2023. At Gilead Sciences, Alison Blaschke Benner also held Associate Director (2022–2023), Senior Manager (2020–2022) and Manager (2019–2020) titles in Alliance Management, and Manager, Regulatory Affairs: US Product Lead (2018–2020).
Aoife Ryan
LinkedInExperience: Director, Alliance Management · Gilead Sciences
Aoife Ryan has been Director, Alliance Management at Gilead Sciences since September 2024, and was Associate Director, Alliance Management there (2022–2024). At Research Ireland, Aoife Ryan worked in Enterprise Partnerships (2020–2022) and was International Development Manager (2018–2022) and Scientific Programme Manager (2015–2018).
Bill Mendez
LinkedInExperience: Vice President Alliance Management · Gilead Sciences
Bill Mendez has been Vice President Alliance Management at Gilead Sciences since August 2021. At GSK, Bill Mendez was Vice President Alliance Management, BD Strategy & Operations Pharmaceuticals R&D (2016–2021), Vice President Global Strategy, Business Development & Strategic Alliances (2009–2021) and Vice President R&D Procurement (2013–2016).
Daniel B. Tumas
LinkedInExperience: VP, Search and Evaluation, Corporate Development · Gilead Sciences
Daniel B. Tumas has been VP, Search and Evaluation, Corporate Development at Gilead Sciences since February 2017, a role the profile describes as leading search and evaluation within corporate development. The profile also cites drug discovery and development experience at Genentech, Millennium and Gilead and at the NIH.
JaeB Kim, PhD, MBA
LinkedInExperience: Director, Alliance Management · Gilead Sciences
JaeB Kim has been Director, Alliance Management at Gilead Sciences since April 2022. At Samsung Biologics, JaeB Kim was Managing Director, Head of Site (2021–2022), Senior Director, Head of Alliance Management Team (2020–2021) and Senior Director, Global Business Development (2020).
Rachel Bright
LinkedInExperience: Executive Director, Alliance Management · Gilead Sciences
Rachel Bright has been Executive Director, Alliance Management at Gilead Sciences since January 2021, and held Sr. Director (2018–2021), Director (2017) and Associate Director (2015–2017) titles in Alliance Management at Gilead Sciences. Rachel Bright was Director, Alliance Management and Business Development at GRAIL (2017–2018).
Robert Lam
LinkedInExperience: Senior Director, Corporate Development · Gilead Sciences
Robert Lam has been Senior Director, Corporate Development at Gilead Sciences since August 2026, and was Director, Corporate Development there (2023–2026). Robert Lam was Director, Business Development at Sana Biotechnology, Inc. (2021–2022) and at CytomX Therapeutics (2020–2021), and Associate Director, Business Development at CytomX Therapeutics (2018–2020).
Sarah E. Warren
LinkedInExperience: Senior Director, Business Development - Cell Therapy Search and Evaluation · Gilead Sciences
Sarah E. Warren has been Senior Director, Business Development - Cell Therapy Search and Evaluation at Gilead Sciences since January 2024, and was Senior Director, Research Technology and Business Development Planning at Kite Pharma (2022–2024). Sarah E. Warren held Senior Director, Translational Science (2019–2022) and Director, Advanced Applications - Immune Oncology (2017–2019) roles at NanoString Technologies, Inc.
Sarah Rabbad, MBA
LinkedInExperience: Director, Intellectual Property Alliance & Corporate Development · Gilead Sciences
Sarah Rabbad has been Director, Intellectual Property Alliance & Corporate Development at Gilead Sciences since December 2025, and held Associate Director (2024–2025) and Senior Manager (2022–2024) titles in Intellectual Property Alliance & Corporate Development there. Sarah Rabbad was Legal Operations Manager at Imperva (2018–2019) and at Caribou Biosciences (2015–2018).
Wendy Peters
LinkedInExperience: Former Senior Director Corporate Development · Gilead Sciences
Former Senior Director Corporate Development at Gilead Sciences (2023–2025). Wendy Peters has been Head of S&E Immunology at AbbVie since January 2025, and was Senior Director, Emerging Science & Innovation Lead, Inflammation and Immunology at Pfizer (2019–2023) and Director External Science and Partnering, Immunology and Inflammation at Sanofi (2015–2019).
Choose the right perspective
Pick someone from search and evaluation or corporate development for questions about how outside opportunities are found and assessed, and someone from alliance management for questions about running a partnership once it is signed. Match the person's therapeutic or functional focus in their title to your question where the title names one.
Questions to take into the conversation
- 01How does a biopharma search and evaluation group decide which outside programs deserve a closer look?
- 02What does alliance management involve once a drugmaker signs a partnership?
- 03How do corporate development and intellectual property teams work together on a licensing opportunity?
Reaching Gilead business development leaders
How can I contact one of these Gilead business development leaders?
Pick one of the 10 people on this page and choose "Book a paid call", or describe your project to find others. You offer a fee for a 15-minute call or a written answer, Instant Expert finds the person's work email and sends the invitation, and they decide whether to accept. The list covers 1 company: Gilead Sciences, based on profile data retrieved on October 26, 2026. Being listed here doesn't mean someone has agreed to take calls.
How much does it cost to reach Gilead business development leaders?
You choose the offer, starting at $5 per person. The offer is what the person receives, and Instant Expert's fee is added on top, so a $100 offer costs you $125. The fee is 20% of what you pay. You're charged only when the person books the call or sends the answer.
What if they don't reply?
You pay nothing. Instant Expert sends follow-up reminders, and if the person hasn't booked or answered within 7 days, the request expires and any hold on your card is released. You can invite several of the 10 people on this list at once and cap your total spend, so you pay only for the ones who accept.
Can an AI agent ask one of these Gilead business development leaders a question?
Yes. An agent with a USDC wallet on Base can ask one question without an Instant Expert account. It names the person, for example by the LinkedIn URL on this page, and pays per ask over x402 (HTTP 402). The person answers in writing or by voice note, and if nobody answers within 7 days, the payment goes back to the wallet automatically. Claude and ChatGPT can do the same through the Instant Expert connector: setup is at /docs/mcp for Claude and /docs/chatgpt for ChatGPT. x402 docs
About this directory
This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot; roles marked former had ended by then. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.